Exodus Point Capital Management, LP Adc Therapeutics Sa Transaction History

Exodus Point Capital Management, LP

  • $14.6 Billion
  • Q4 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$4.66 - $10.31 $1.07 Million - $2.37 Million
230,194 Added 165.38%
369,386 $1.78 Million
Q2 2022

Aug 19, 2022
BUY
$5.96 - $14.99 $829,584 - $2.09 Million
139,192 New
139,192 $1.11 Million
Q4 2020

Feb 16, 2021
SELL
$25.26 - $38.02 $2.06 Million - $3.1 Million
-81,624 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$32.87 - $51.05 $2.11 Million - $3.28 Million
64,199 Added 368.43%
81,624 $2.69 Million
Q2 2020

Aug 14, 2020
BUY
$29.65 - $46.81 $516,651 - $815,664
17,425 New
17,425 $816,000

Others Institutions Holding ADCT

# of Institutions
85
Shares Held
53.5M
Call Options Held
28K
Put Options Held
60.4K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $124M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Exodus Point Capital Management, LP Portfolio

Follow Exodus Point Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Exodus Point Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email